(Sorrento) Sorrento Therapeutics Inc. has announced an 81% sensitivity by COVISTIX for screening both symptomatic and asymptomatic Covid-19 infections.
The 81% sensitivity is a superior rate compared to 62% reported for the globally leading Panbio rapid antigen test. Sorrento’s study involved 783 participants, compared to 2,202 in the Panbio antigen test.
The higher sensitivity implies fewer false negatives, an important milestone in reducing the spread of Covid infections.
The specificity rate of COVISTIX was reported at 96%, lower than Panbio at 99.0%.
SRNE: NASDAQ is up +2.55% on premarket.
